Floatz logo

Zometa

Without Her 2 Overexpression

Hospices Civils de LyonPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Without Her 2 Overexpression cohort.

Asset / SponsorPhaseRating
LENVATINIB
Hospices Civils de Lyon
Phase 2B
Tislelizumab
Hospices Civils de Lyon
Phase 2B

Same molecule, other indications

Zometa is also rated in:

metastatic carcinoma in the boneDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
64 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →